Back

The impact of loop diuretics reduction on heart failure rehospitalization in post-TAVR patients

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Aortic stenosis: cause, treatment, and outcome Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Koki Takegawa

National Cerebral & Cardiovascular Center, Suita (Japan)

5 More presentations in this session

Presentation thumbnail
Inflammatory burden index and mortality following transcatheter aortic valve replacement
Doctor S. Kikuchi (Strasbourg, FR)
Abstract Slides Video
Presentation thumbnail
Can HALP help in identifying transcatheter aortic valve replacement patients at risk?
Doctor P. Bistrovic (Zagreb, HR)
Abstract Slides Video
Presentation thumbnail
Association between deployment depth eccentricity index and hypo-attenuated leaflet thickening after transcatheter aortic valve replacement
Professor Y. Li (Xi'an, CN)
Abstract Slides Video
Presentation thumbnail
Awake-TAVI: Impact of anesthesia techniques on peri- and postoperative outcomes in TAVI patients
Doctor R. Phinicarides (Duesseldorf, DE)
Abstract Slides Video
Presentation thumbnail
Association between transcatheter heart valve type and periprocedural myocardial injury in transcatheter aortic valve implantation
Doctor L. Waldschmidt (Hamburg, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Aortic stenosis: cause, treatment, and outcome

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Clinical characteristic of LVAD recipients required over and lower than median dosage of loop diuretic during 12 month following the implantation
thumbnail
Congress Presentation
Effects of intravenous loop diuretic dose and delivery on congestion, natriuretic peptides, diuretic efficiency, and urinary sodium: findings from the DIUR-AHF Trial
thumbnail
Congress Presentation
The impact on CD146 congestion biomarker by early adding SGLT2i dapaglifozin to intravenous loop diuretic in patients with acute heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources